Phase II study of pemetrexed or pemetrexed plus bevacizumab for previously untreated elderly non-squamous non-small cell lung cancer
Phase 2
- Conditions
- Previously untreated elderly non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000008771
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 82
Inclusion Criteria
Not provided
Exclusion Criteria
1) symptomatic brain metastasis 2) complications as follows: hemoptysis, arterial and venous thromboembolism, uncontrolled hypertension, perforation of the digestive tract/severe fistula/bronchoesophageal fistula, inflammation in abdominal cavity, congenital bleeding predisponency/abnormality of hemostasis, uncontrolled diabetes 3) operation within 28 days 4) planning of thoracic radiotherapy in bevacizumab therapy 5) symptomatic pericardial effusion 6) symptomatic SVC syndrome 7) interstitial pneumonia confirmed in chest X-ray 8) psychotic disease judged should not to participate the trial 9) other inadequacy cases judged by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method